Idel Therapeutics raised €9 million (about $10.4 million) seed funding to advance cytotoxic intracellular drug delivery technology directly into tumor cell cytosol. The company’s platform targets intracellular delivery for mechanisms aimed at previously difficult-to-drug targets. Idel’s financing highlights continued investor appetite for delivery-first oncology platforms that can expand the addressable target space beyond surface receptors and secreted biomarkers. The company’s stated goal is to progress its technology development and support early-stage studies through the next steps toward therapeutic candidates. For biotech participants, delivery modality investments remain a leading category because they can create differentiation without needing a fully de novo target biology story at the earliest stages. The funding also signals that intracellular delivery approaches are reaching a level of technical readiness sufficient to justify external capital and continued translational development.